Agilent Technologies (NYSE: A) Stock Analysis: Strong Financials Drive Analyst Confidence in Scientific Instruments Market

• Agilent Technologies (NYSE: A) reported robust Q3 2026 financial results, significantly beating analyst estimates for both earnings per share and revenue.
• Citigroup (NYSE: C) reaffirmed its "Buy" rating and raised its price target for Agilent, signaling strong analyst confidence in the company's stock performance.
• The company has raised its profit forecast for the year, citing increased demand for its medical tools and lab equipment, which underpins a positive future outlook.

Agilent Technologies (NYSE: A) is a leading provider of scientific instruments, offering essential tools and laboratory equipment to researchers and laboratories, particularly in critical areas like drug development. This prominent player in the life sciences industry boasts a substantial market capitalization of around $43.82 billion, reflecting its significant presence in the market.

On August 27, 2026, leading financial institution Citigroup (NYSE: C) reaffirmed its "Buy" rating for Agilent Technologies. Demonstrating increased confidence in the stock's potential, Citigroup also elevated its price target for Agilent shares to $190.00, up from a prior target of $185.00. This revised target indicates the price an analyst anticipates the stock will achieve. At the time of the rating's publication, Agilent's stock price stood at $155.17.

This positive analyst sentiment is firmly underpinned by Agilent's robust financial performance. For its third quarter of 2026, Agilent reported impressive earnings per share (EPS) of $1.62. As highlighted by Zacks Investment Research, this figure significantly surpassed the average analyst estimate of $1.48 per share, leading to a substantial earnings surprise of 9.46%. This strong earnings report underscores the company's operational efficiency.

Furthermore, Agilent Technologies showcased healthy revenue growth. The company generated $1.88 billion in revenue, marking an impressive 8.1% increase compared to the corresponding quarter of the previous year. This strong revenue figure also exceeded the Zacks Consensus Estimate by 2.08%. Agilent's consistent ability to surpass revenue expectations over the past three quarters highlights its market strength and effective business strategies.

Looking ahead, Agilent Technologies has proactively raised its profit forecast for the entire year, as reported by Thomson Reuters (NYSE: TRI). The company attributes this optimistic revision to sustained strong demand for its specialized medical tools and lab equipment. This enhanced outlook provides a solid foundation for the heightened confidence expressed by analysts concerning Agilent's future stock performance and investment potential.